Related Experiment Video
Updated: Jan 1, 2026

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
Published on: December 30, 2025
The p53-reactivating small molecule RITA induces senescence in head and neck cancer cells
Hui-Ching Chuang1, Liang Peng Yang2, Alison L Fitzgerald3
1Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America; Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Abstract:
TP53 is the most commonly mutated gene in head and neck cancer (HNSCC), with mutations being associated with resistance to conventional therapy. Restoring normal p53 function has previously been investigated via the use of RITA (reactivation of p53 and induction of tumor cell apoptosis), a small molecule that induces a conformational change in p53, leading to activation of its downstream targets. In the current study we found that RITA indeed exerts significant effects in HNSCC cells. However, in this model, we found that a significant outcome of RITA treatment was accelerated senescence. RITA-induced senescence in a variety of p53 backgrounds, including p53 null cells. Also, inhibition of p53 expression did not appear to significantly inhibit RITA-induced senescence. Thus, this phenomenon appears to be partially p53-independent. Additionally, RITA-induced senescence appears to be partially mediated by activation of the DNA damage response and SIRT1 (Silent information regulator T1) inhibition, with a synergistic effect seen by combining either ionizing radiation or SIRT1 inhibition with RITA treatment. These data point toward a novel mechanism of RITA function as well as hint to its possible therapeutic benefit in HNSCC.
Insights
RITA treatment accelerates senescence in head and neck cancer (HNSCC) cells, a process partly independent of TP53 mutations. This finding suggests novel therapeutic strategies for HNSCC by combining RITA with DNA damage response activators or SIRT1 inhibitors.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- TP53 gene mutations are prevalent in head and neck squamous cell carcinoma (HNSCC) and linked to therapeutic resistance.
- RITA (reactivation of p53 and induction of tumor cell apoptosis) is a small molecule designed to restore p53 function and induce cancer cell death.
Purpose of the Study:
- To investigate the effects of RITA on HNSCC cells.
- To elucidate the mechanism of RITA's action, particularly concerning senescence induction.
Main Methods:
- Treatment of HNSCC cell lines with RITA.
- Analysis of p53 status, senescence markers, DNA damage response activation, and SIRT1 activity.
- Combination studies with ionizing radiation and SIRT1 inhibition.
Main Results:
- RITA induced significant effects in HNSCC cells, primarily accelerated senescence.
- RITA-induced senescence occurred across various p53 backgrounds, including p53-null cells, indicating partial p53 independence.
- Senescence was partially mediated by DNA damage response activation and SIRT1 inhibition, with synergistic effects observed when combined with RITA.
Conclusions:
- RITA exhibits a novel mechanism of action in HNSCC, inducing p53-independent senescence.
- The findings suggest potential therapeutic benefits of combining RITA with agents targeting the DNA damage response or SIRT1 for HNSCC treatment.
Related Concept Videos
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Negative Regulator Molecules
Abnormal Proliferation
Replicative Cell Senescence
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

